Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI), which is changing its corporate name to Axe Compute Inc. with an expected ticker transition to AGPU, generates news at the intersection of AI‑driven oncology, capital markets activity, and digital asset‑enabled AI infrastructure. Company announcements emphasize its use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for cancer patients, as well as its newer digital asset treasury strategy focused on ATH, the native utility token of the Aethir network.
News updates frequently cover financial results and corporate updates, including quarterly earnings releases, shareholder letters, and discussions of operating performance. These communications often describe progress in validating proprietary technologies, such as the PEDAL AI platform and the ChemoFx live‑cell tumor profiling assay, along with efforts to expand the availability of ChemoFx in the United States and prepare for a de novo launch in Europe.
Investors following POAI can also expect transaction and financing news, such as private placements involving cash and digital assets, reverse stock split announcements, at‑the‑market offering updates, and standby equity purchase agreements. Recent disclosures describe substantial private investment in support of the company’s digital asset treasury strategy, as well as Nasdaq compliance updates related to stockholders’ equity and bid price requirements.
Another recurring theme in the news flow is strategic partnerships and governance developments. Examples include the strategic collaboration with Every Cure on drug repurposing, collaborations related to 3D liver toxicity models, and appointments of new board members and senior leaders to support the digital asset treasury and AI initiatives. Updates on the evolution of the company’s business model, including the creation of a Strategic Compute Reserve through ATH holdings on the Aethir ecosystem, are also highlighted.
For readers and investors, the POAI news page provides a consolidated view of these developments, allowing closer tracking of the company’s oncology‑focused AI activities, its digital asset strategy, and key regulatory and listing milestones.
Predictive Oncology (POAI) is enhancing its capabilities through the acquisition of zPREDICTA, a leader in cancer solutions, known for its patented 3D cell culture platform. This strategic move aims to expand POAI's reach in personalized cancer therapies, leveraging zPREDICTA's established revenue streams and client base in pharmaceutical sectors. The acquisition, alongside the hiring of Pamela Bush to lead sales efforts, supports POAI's transition from R&D to a revenue-generating biopharmaceutical company.
Predictive Oncology (POAI) has announced the appointment of Pamela Bush, Ph.D., MBA, as SVP of Strategic Sales and Business Development. With nearly 20 years of experience, Bush aims to commercialize the company's innovative cancer research technologies. CEO Mel Engle highlighted her role in optimizing treatment predictions for pharmaceutical and healthcare partners. Additionally, Bush will assist in business development and integrate the recently acquired zPREDICTA into the company's offerings.
Predictive Oncology (POAI) has acquired zPREDICTA, enhancing its portfolio with a patented 3D cell culture platform aimed at improving cancer therapy development. This acquisition is expected to provide an immediate revenue stream and long-term growth due to anticipated synergies. zPREDICTA specializes in tumor-specific models that closely mimic human cancer environments, which is vital for drug discovery. The integration of zPREDICTA’s technology with Predictive Oncology's AI-driven database promises to enhance treatment outcome predictions, delivering greater insights for pharmaceutical partners.
Predictive Oncology (POAI) reported its Q3 2021 financial results, highlighting a reduced loss per share of $0.08 from $0.46 in Q3 2020. Revenue for the quarter was $313,663, down from $480,757 year-over-year, primarily due to decreased sales of STREAMWAY System units. Cash increased significantly to $41 million for the nine months ended September 30, 2021, compared to $2.3 million in 2020. The company has no outstanding debt and reported operational cash usage decreased. The gross profit margin remained steady at approximately 65%.
Predictive Oncology is advancing cancer research via AI technologies aimed at improving drug discovery and clinical outcomes. As of October 19, 2021, the company launched a new website showcasing its mission and subsidiaries: Helomics, Soluble Biotech, and TumorGenesis. These entities work collaboratively to predict treatment outcomes and develop optimized cancer drugs. Helomics utilizes a vast database and AI for personalizing therapies, while Soluble Biotech streamlines protein formulation. TumorGenesis focuses on studying ovarian cancer cells for better treatment insights.
Predictive Oncology (NASDAQ: POAI) announced the election of Raymond F. Vennare to its Board of Directors effective September 13, 2021. Vennare has over 30 years of experience in biotechnology and has held leadership positions in multiple companies, including as CEO of Cvergenx, Inc. His expertise spans company creation, technology commercialization, and corporate governance. CEO J. Melville Engle expressed excitement about Vennare joining the board, stating he will provide valuable perspective and leadership in oncology.
Predictive Oncology (Nasdaq: POAI) announced that stockholders approved an amendment to increase the number of authorized shares from 100 million to 200 million, effective August 17, 2021. This decision was made at a special stockholder meeting held on August 10, 2021, which was adjourned to August 17, 2021. The company utilizes AI for personalized medicine and drug discovery through its segments: Skyline, Helomics, and Soluble Biotech.
Predictive Oncology (POAI) reported strong financial results for Q2 2021, highlighting revenue of $350,207, a 92% increase from the previous year. The company's cash balance rose to $44.9 million, up from $3.4 million in 2020, following a $19.4 million equity offering. Total Stockholders’ Equity surged to $53.1 million. Key developments include the partnership with Cellevate AB and the construction of new GMP facilities expected to enhance revenue growth. CEO J. Melville Engle indicated confidence in retaining growth momentum through strategic investments in personnel and technology.
Predictive Oncology (Nasdaq: POAI) announced that its Special Meeting of Stockholders, held on August 10, 2021, has been adjourned to solicit more votes for the Charter Proposal, which aims to double the authorized shares from 100 million to 200 million. The reconvened meeting is set for August 17, 2021. Other proposals, including an increase in stock incentive plan shares and the appointment of an independent auditor, were approved. The Charter Proposal is now considered 'routine' under NYSE rules, allowing brokers to vote without instruction if beneficial owners do not respond.
Predictive Oncology (NASDAQ: POAI) has announced promising initial results from its subsidiary Helomics' AI models predicting ovarian cancer outcomes using genomic data. The model, developed with data from the 100,000 Genomes Project, shows nearly 70% accuracy in predicting post-treatment survival rates for ovarian cancer patients. This innovation aims to personalize therapies and improve patient prognoses, addressing the lack of biomarkers in ovarian cancer treatment. The results will be available as a preprint on Biorxiv this summer.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
